CYPH (Cypherpunk Technologies) Valuation Rank


CYPH Cypherpunk Technologies Inc CYPH
28 GF Score
Price $0.65
! 3 Warning Signs
View Full Analysis

What is Cypherpunk Technologies Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cypherpunk Technologies Valuation Rank Related Terms

CYPH
28GF Score
Cypherpunk Technologies Inc CYPH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cypherpunk Technologies Business Description

Other Exchanges 5MC:Germany
Address 47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
28GF Score

Get the complete analysis for CYPH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price